Relmada Therapeutics, Inc.

The momentum for this stock is not very good. Relmada Therapeutics, Inc. is not a good value stock. Relmada Therapeutics, Inc. is not a good growth stock. Relmada Therapeutics, Inc. is a mediocre stock to choose.

News

Relmada Therapeutics (NASDAQ:RLMD) Trading 16.3% Higher

Zolmax Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report)'s stock price traded up 16.3% during mid-day trading on Monday . The company traded as high as $2.95 and last traded at $2.79. 294,216...\n more…

Insiders Who Purchased US$663.4k Of Relmada Therapeutics Stock May Not Have Expected 14% Tumble

Simply Wall St The recent price decline of 14% in Relmada Therapeutics, Inc.'s ( NASDAQ:RLMD ) stock may have disappointed insiders...\n more…

Relmada Therapeutics files $250M mixed securities shelf

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Vanguard Group Inc. Has $5.84 Million Holdings in Relmada Therapeutics, Inc. (NASDAQ:RLMD)

Zolmax Vanguard Group Inc. reduced its stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) by 4.1% during the first quarter, HoldingsChannel reports. The firm owned 1,256,705 shares of the...\n more…

Q3 2024 EPS Estimates for Relmada Therapeutics, Inc. (NASDAQ:RLMD) Lifted by Leerink Partnrs

Ticker Report Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Analysts at Leerink Partnrs raised their Q3 2024 earnings per share estimates for shares of Relmada Therapeutics in a research note issued on...\n more…

Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research A downtrend has been apparent in Relmada Therapeutics, Inc. (RLMD) lately with too much selling pressure. The stock has declined 43.4% over the past four weeks. However, given the fact that it is now...\n more…